Psychiatry

Taylor’s clues and Ripley’s secrets – what you should see and listen to this week

Retrieved on: 
Friday, April 19, 2024
Amorality, Psychiatry, Human, Noise, Music, Darkness, National Library of Wales, Mental health, Research, Sale, Politics, Talent, Design Museum, Suicidal ideation, Ambiguity, Animal, Love, Music of Wales, Emotion, National library, Singing

Over the past few weeks, Taylor Swift has planted clues about her 11th album, The Tortured Poets Department, which is finally released today.

Key Points: 
  • Over the past few weeks, Taylor Swift has planted clues about her 11th album, The Tortured Poets Department, which is finally released today.
  • The announcement of the album at this year’s Grammys took everyone, including her devoted Swifties, by surprise.
  • A popular theory among Swifties is that track five on her albums is where she really exposes her raw emotions.
  • Read more:
    I've researched Clara Bow – it's no wonder the actress inspired Taylor Swift's new album

What lurks beneath

  • In the film Sometimes I Think About Dying, protagonist Fran also has a lot going on beneath her calm surface.
  • A shy and withdrawn office worker, her days are filled with menial tasks and painfully mundane experiences.
  • The monotony of it all allows for moments where her mind wanders into darkness, imagining the various ways she could die.

Welsh up-and-comers and Italian greats

  • Singing is deeply woven into Welsh culture and traditions and it’s home to many greats – Shirley Bassey, Tom Jones, Stereophonics, Super Furry Animals and Manic Street Preachers to name a few.
  • I’ve been listening to one of their recs, Cerys Hafana, whose minimalist electronic folk draws on traditional Welsh music to create hypnotic tracks.
  • Read more:
    Enzo Mari at the Design Museum explores how the giant of Italian design saw his work as a political act


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.

Clearmind Medicine CEO Issues Letter to Shareholders

Retrieved on: 
Tuesday, April 9, 2024
Data monitoring committee, Depression, Obesity, Mevalonate pathway, Psychiatry, Dyskinesia, Addiction, Safety, Binge drinking, Data, DSM-IV codes, Research, MEAI, Clinical trial, Johns Hopkins University, Phase, Patent, Therapy, Ministry, FDA, Impulsivity, CTS, IRB, Pharmaceutical industry

Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.

Key Points: 
  • Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.
  • CMND-100, a pioneering MEAI-based (5-methoxy-2-aminoindane) formula, has exhibited encouraging results in pre-clinical studies.
  • Notably, it has shown the ability to disrupt the destructive cycle of binge drinking without inducing hallucinations—a common concern with existing treatments.
  • The journey ahead is filled with potential, and we eagerly anticipate sharing impactful updates with our shareholders."

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

Retrieved on: 
Friday, April 5, 2024
Psychiatry, Growth, Capsule, Research, MDXX, GMP, OTC, MDMA, Pharmaceutical industry

TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, in another Australian first, its joint venture, Cortexa Pty.

Key Points: 
  • TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, in another Australian first, its joint venture, Cortexa Pty.
  • Ltd. (“Cortexa”), is proud to have commenced batch manufacturing of GMP LaNeo® MDMA 40mg capsules to support both clinical trials and clinical use under the TGA’s Authorised Prescriber pathway.
  • In doing so, Cortexa achieves another significant milestone, domestic Australian manufacturing, further strengthening its position as a leader in the Australian psychedelic landscape by executing on its plan to develop a reliable local supply.
  • After a comprehensive due diligence process, Cortexa is pleased to announce it has entered an exclusive arrangement with Perth-based contract manufacturer Optima Ovest (Optima).

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on: 
Thursday, March 28, 2024
MEG, Development, Psychiatry, Veteran, Physician, Post-traumatic stress disorder, NSI, Analysis of variance, Patient, UC, RPQ, Jesse Russell, Radiology, Human services, PCS, Concussion, Trial of the century, University, McGill Pain Questionnaire, Brain damage, Pain, ANOVA, Vaccine, PTSD, MPQ, Medical imaging

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points: 
  • mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
  • The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
  • Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group

Retrieved on: 
Wednesday, March 27, 2024
Depression, Neuropsychiatry, Partner, Psychiatry, ADHD, Mental, Partnership, LMHC, Transcranial magnetic stimulation, TMS, News, Acquisition, Brain, Region, Physician, Health, Dementia, Practitioner, Nursing

"We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.

Key Points: 
  • "We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.
  • Established in 2016, The Neuropsychiatry & TMS Group, led by Dr. Ahmed, has been dedicated to delivering exceptional mental health services.
  • With the support of Beacon, The Neuropsychiatry & TMS Group anticipates continued growth opportunities, including expanding its TMS services and recruiting additional physicians.
  • “I am pleased to announce our recent expansion into Florida, a natural progression for Beacon,” says Beacon Behavioral Partners CEO Sean Wendell.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Conference, Depression, ADAA, Anxiety, Clinical trial, DSM-IV codes, Signs and symptoms, Premenstrual dysphoric disorder, Social anxiety disorder, Psychiatry, SAD, Publication

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.
  • Title: PH80 Nasal Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder: Results from a Phase 2a Study
    The posters will be available on the Publications page of Vistagen’s website on Monday, April 15, 2024.
  • In addition to presenting fasedienol and PH80 clinical data, Vistagen will receive the ADAA 2024 Partner Recognition Award, recognizing Vistagen as a partner organization that has consistently contributed to the success of ADAA’s annual conference and supported ADAA’s public and professional mission.
  • Vistagen and ADAA are committed to redefining the future of mental health care and bringing hope to millions of individuals affected by debilitating mental health disorders.

Abusive Referrals for Psychiatric Assessment Are a Tool of Sham Physician Peer Review, according to Journal of American Physicians and Surgeons

Retrieved on: 
Thursday, March 21, 2024
Mere, Psychiatry, Intellectual, Abuse, Journal, Hospital, Rehabilitation, Rehabilitation Act of 1973, Disability discrimination act, AAPS, Physician, Person, Nursing

One technique for physicians who fail to conform to official government narratives is mandatory referral for psychiatric or neuropsychological testing, writes neurologist Lawrence Huntoon, M.D ., in the spring issue of the Journal of American Physicians and Surgeons.

Key Points: 
  • One technique for physicians who fail to conform to official government narratives is mandatory referral for psychiatric or neuropsychological testing, writes neurologist Lawrence Huntoon, M.D ., in the spring issue of the Journal of American Physicians and Surgeons.
  • “Hearsay, rumor, and suspicion are often all that is needed to force physicians to undergo psychiatric and neuropsychological testing,” he writes.
  • A 2019 Resolution passed by the Association of American Physicians and Surgeons (AAPS) condemns the abuse and misuse of psychiatry in physician evaluation as unethical.
  • It states that abuse occurs when referrals are made to support illegitimate purposes or when evaluees are denied full due process.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Retrieved on: 
Wednesday, March 13, 2024
Dopamine, NET, Reward, Sheba Medical Center, CWY, Psychiatry, Serotonin, Patient, Research, MEAI, Alcoholism, Clinical trial, DAT, Safety, Norepinephrine, Yale school, Therapy, Ministry, Pharmaceutical industry

The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Key Points: 
  • The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.
  • The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer

Retrieved on: 
Thursday, April 4, 2024
Mental Health, Health, Hospitals, Physical Therapy, Managed Care, General Health, Psychiatry, Patient, Mental health, Child, University, Adolescence, Pediatrics, Acadia Healthcare, Safety, Multimedia, Medical device

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the appointment of Dr. Stephanie Eken as the Company’s new chief medical officer.

Key Points: 
  • Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the appointment of Dr. Stephanie Eken as the Company’s new chief medical officer.
  • View the full release here: https://www.businesswire.com/news/home/20240404108920/en/
    Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer (Photo: Business Wire)
    “Acadia is thrilled to welcome Dr. Eken as our new chief medical officer,” said Chris Hunter, Chief Executive Officer of Acadia Healthcare.
  • “This is an exciting time to join Acadia Healthcare,” said Dr. Eken.
  • Dr. Genovese departs Acadia after 10 years with the Company, seven of those as its chief medical officer.